Tenax Therapeutics Inc TENX:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/01/21 EST
2.19quote price arrow up+0.04 (+1.86%)
Volume
131,803
52 week range
0.25 - 3.68

...

Loading . . .

KEY STATS

  • Open2.25
  • Day High2.30
  • Day Low2.19
  • Prev Close2.19
  • 52 Week High3.68
  • 52 Week High Date01/27/21
  • 52 Week Low0.25
  • 52 Week Low Date03/12/20
  • Market Cap31.78M
  • Shares Out14.51M
  • 10 Day Average Volume0.33M
  • Dividend-
  • Dividend Yield-
  • Beta2.35
  • 1 Year % Change85.64

RATIOS/PROFITABILITY

  • EPS (TTM)-1.20
  • P/E (TTM)-1.82
  • Fwd P/E (NTM)-4.06
  • EBITDA (MRQ)-9.844M
  • ROE (MRQ)-140.79%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)3.30%

EVENTS

  • Earnings Date03/31/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Tenax Therapeutics Inc News

There is no recent news for this security.

Latest TENX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other...
Ronald Blanck
Chairman
Anthony DiTonno
Chief Executive Officer
Michael Jebsen CPA
President
Doug Randall
Executive Vice President
Douglas Hay Ph.D.
Executive Vice President
Address
One Copley Parkway, Suite 490
Morrisville, NC
27560
United States